Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival. Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF in early-phase trials.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

PASSAMONTI, FRANCESCO
Writing – Original Draft Preparation
;
2015

Abstract

Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival. Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically beneficial activity in patients with MF in early-phase trials.
Pardanani, Animesh; Harrison, Claire; Cortes, Jorge E.; Cervantes, Francisco; Mesa, Ruben A.; Milligan, Donald; Masszi, Tamás; Mishchenko, Elena; Jourdan, Eric; Vannucchi, Alessandro M.; Drummond, Mark W.; Jurgutis, Mindaugas; Kuliczkowski, Kazimierz; Gheorghita, Emanuil; Passamonti, Francesco; Neumann, Frank; Patki, Abhay; Gao, Guozhi; Tefferi, Ayalew
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11383/2024081
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 120
  • Scopus 253
  • ???jsp.display-item.citation.isi??? 242
social impact